Article info
PDFOriginal research
Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups
- Correspondence to Dr Gabriella Macchia, Radiation Oncology Unit, Gemelli Molise, Campobasso 86100, Molise, Italy; macchiagabriella{at}gmail.com
Citation
Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups
Publication history
- Received November 17, 2021
- Accepted February 3, 2022
- First published February 22, 2022.
Article Versions
- You are currently viewing a Previous version of this article (15 November 2022).
- View the most recent version of this article
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.